Stock screener

FATE

Conviction 99HealthcareScan · Mon, Aug 10, 2026
FATE$2.75-1.79%
ResistanceSupportVol 14Insider sell
63 bars
2
2
Vol MA14 2.59M
May 11May 28Jun 16Jul 6Jul 23Aug 10
FATE THERAPEUTICS INCBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.fatetherapeutics.com
Price2.75
Change-1.79%
Gap+0.00%
Rel volume3.41×
Avg volume2.48M
Avg $ vol6.58M
SMA 202.62
SMA 502.48
SMA 2001.60
Price vs 50+10.70%
Price vs 200+71.54%
MA stackbullish
50/200 cross
Supertrendup · 2.22
RSI (14)56
MACD hist0.01
MACD crossbull · 0d
Stoch %K / %D79 / 68
ADX (14)17
+DI / −DI22 / 18
RSI divergence
MACD divergence
ATR %+7.72%
ADR %7.13%
52w high3.11
52w low0.9214
From 52w high-11.58%
Above 52w low+198.46%
New 52w highNo
SqueezeOff
Bollinger width29.76%
%B0.67
Donchian pos59.17%
Donchian high3.10
Donchian low2.25
AVWAP (52w high)2.70
vs AVWAP high+1.77%
AVWAP (52w low)1.75
vs AVWAP low+56.80%
OBV trendFlat
Chaikin MF (20)-0.21
Today vs 20d3.41×
Avg vol (14d)2.59M
Avg vol (20d)2.48M
Avg $ vol (20d)6.58M
Market cap320.54M
RS 3m (vs SPY)+9.53%
RS 6m (vs SPY)+152.55%
RS line new highNo
Trend template8/8
Technical rank80.2
1 week+10.00%
1 month-11.29%
3 months+15.06%
6 months+141.23%
1 year+180.58%
YTD+178.79%
P/E-2.35
P/B1.78
P/S48.23
P/FCF-2.86
EPS-1.15
Div yield
ROE-75.85%
ROA-47.84%
Debt/Eq0.13
Current5.85
EV/EBITDA-2.26
Gross margin
Net margin
Rev growth-51.24%
EPS growth26.82%
Price target5.24
Target upside90.55%
Analyst ratingBuy
Institutional67.73%
Ent. value304.37M
Revenue1.3M
Net income-31.21M
Gross profit
Free cash flow-112.04M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out
Employees161
ListedTue, Oct 1, 2013
Free float98.83M
Float %85.0%
Short interest7.32M
Days to cover2.0d
Short volume54.6%
Squeeze score49 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.26 vs −$0.29
Last surprise+10.3% beat
Setup gradeA+
Conviction99 / 100
Pattern quality
Tech rank80.2 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance3.22
Support1.84
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in FATE

All disclosures →
No recent disclosed trades by Congress in FATE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in FATE · 3 buys · 6 sells

InsiderSideShares
Valamehr Bahram
President and CEO · Common Stock · 2026-08-04
Sell43.95K
TAHL CINDY
See Remarks · Common Stock · 2026-08-04
Sell38.8K
Valamehr Bahram
President and CEO · Common Stock · 2026-05-20
Sell28.95K
TAHL CINDY
See Remarks · Common Stock · 2026-05-20
Sell25.59K
TAHL CINDY
See Remarks · Common Stock · 2026-05-06
Exercise122.22K
TAHL CINDY
See Remarks · Stock Option (Right to Buy) · 2026-05-06
Exercise44.44K
TAHL CINDY
See Remarks · Stock Option (Right to Buy) · 2026-05-06
Exercise122.22K
TAHL CINDY
See Remarks · Common Stock · 2026-05-06
Exercise44.44K
EPSTEIN ROBERT S
Director · Stock Option (Right to Buy) · 2026-05-05
Exercise25K
RASTETTER WILLIAM H
Director · Common Stock · 2026-05-05
Other

SEC filings

EDGAR filings in FATE · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.